Yahoo
Jakarta - Delayed Quote IDR

PT Phapros Tbk (PEHA.JK)

254.00 0.00 (0.00%)
At close: October 30 at 4:00:03 PM GMT+7
Chart Range Bar
Loading chart for PEHA.JK
  • Previous Close 254.00
  • Open 254.00
  • Bid --
  • Ask --
  • Day's Range 252.00 - 266.00
  • 52 Week Range 206.00 - 460.00
  • Volume 61,600
  • Avg. Volume 1,036,090
  • Market Cap (intraday) 213.36B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 5.29
  • EPS (TTM) 48.00
  • Earnings Date --
  • Forward Dividend & Yield 5.01 (1.97%)
  • Ex-Dividend Date Jun 23, 2026
  • 1y Target Est --

PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also provides ethical generic and branded products; and medical devices, as well as toll manufacturing. It also exports its products. The company was founded in 1954 and is headquartered in Jakarta Selatan, Indonesia. PT Phapros Tbk is a subsidiary of PT Kimia Farma Tbk.

www.phapros.co.id

1,273

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is IDX COMPOSITE (^JKSE) .

YTD Return

PEHA.JK
13.71%
IDX COMPOSITE (^JKSE)
41.52%

1-Year Return

PEHA.JK
20.59%
IDX COMPOSITE (^JKSE)
38.21%

3-Year Return

PEHA.JK
57.56%
IDX COMPOSITE (^JKSE)
24.92%

5-Year Return

PEHA.JK
77.15%
IDX COMPOSITE (^JKSE)
23.28%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.98%

  • Return on Assets (ttm)

    6.32%

  • Return on Equity (ttm)

    11.94%

  • Revenue (ttm)

    1.04T

  • Net Income Avi to Common (ttm)

    51.96B

  • Diluted EPS (ttm)

    48.00

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    157.54B

  • Total Debt/Equity (mrq)

    149.48%

  • Levered Free Cash Flow (ttm)

    76.47B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: